NEW YORK, Oct. 14, 2022 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating allegations on behalf of investors of Y-mAbs Therapeutics, Inc. (“Y-mAbs” or the “Company”) YMAB. Those investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, extension 7980.
The investigation concerns whether Y-mAbs and certain of its officers and/or directors have engaged in securities fraud or other illegal business practices.
[Click here for information about joining the class action]
On October 5, 2020, post-marketing, Y-mAbs issued a press release confirming receipt of “a Letter of Denial of Submission from the U.S. Food and Drug Administration (‘FDA’) regarding the Biologics License Application (‘BLA’ ) for omburtamab for the treatment of pediatric patients with CNS/leptomeningeal metastases from neuroblastoma filed in August 2020.” Y-mAbs informed investors that “[u]After a preliminary review, the FDA has determined that certain portions of the BLA’s Chemistry, Manufacturing and Control (‘CMC’) and Clinical modules require additional detail.”
As a result of this news, y-mAbs stock price fell $3.57 per share or 8.56% to close on October 6, 2020 at $38.13 per share.
The Pomerantz law firm, with offices in New York, Chicago, Los Angeles and Paris, is one of the leading law firms in the areas of corporate, securities and antitrust litigation. Founded by the late Abraham L. Pomerantz, known as Dean of the Class Attorney’s Association, the Pomerantz firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz law firm continues the tradition he established and fights for the rights of victims of securities fraud, breaches of fiduciary duty and corporate misconduct. The firm has recovered numerous multi-million dollar claims on behalf of group members. See www.pomerantzlaw.com.
CONTACT:
Robert S Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980
